OMDA
OMDA
US68170A1088
Omada Health, Inc.
Loading chart...

Company Profile

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.

Latest News

Related stocks

CERT
CERT • United States
Certara, Inc.
9.13 USD
1.39B USD 1Y -33.5%
GDRX
GDRX • United States
GoodRx Holdings, Inc.
3.43 USD
1.17B USD 1Y -23.5%
OMCL
OMCL • United States
Omnicell, Inc.
35.82 USD
1.63B USD 1Y +10.7%
TDOC
TDOC • United States
Teladoc Health, Inc.
5.77 USD
1.05B USD 1Y -39.1%
HSTM
HSTM • United States
HealthStream, Inc.
33.13 USD
1.01B USD 1Y +19.5%
SDGR
SDGR • United States
Schrodinger, Inc.
27.28 USD
2.04B USD 1Y +27.4%
PHR
PHR • United States
Phreesia, Inc.
10.81 USD
670.99M USD 1Y -54.2%
PRVA
PRVA • United States
Privia Health Group, Inc.
20.85 USD
2.66B USD 1Y -17.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
-
Max Drawdown (3Y)
-
Sharpe Ratio (3Y)
-
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 89.8 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende